Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals Appoints Dr. Herman Weiss as Vice President, Medical Affairs and Clinical Development
- Accomplished Women's Health Executive to Support Development of JNP Proprietary Product Portfolio -

BOSTON, March 30, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has appointed Herman Weiss, MD, MBA, FACOG, to the newly-created role of Vice President, Medical Affairs and Clinical Development

Juniper Pharmaceuticals, Inc. (PRNewsFoto/Juniper Pharmaceuticals, Inc.)

Working closely with Chief Medical Officer Dr. Bridget Martell, Dr. Weiss will support the development of Juniper's proprietary product portfolio, providing medical, clinical and regulatory expertise for current and future product candidates leveraging its intra-vaginal ring and bioadhesive gel delivery technologies.

"We are thrilled to have recruited such a medical talent to Juniper Pharmaceuticals as we advance our high-value pipeline to address acute and chronic women's health conditions into later stages of clinical development," stated Frank Condella, CEO. "Herman brings that right balance of clinical acumen, business sense, regulatory experience, and deep understanding of the continued needs in women's health."

Dr. Weiss joins Juniper from Teva Pharmaceutical Industries, Ltd., where he served as Global Medical Director Women's Health and Bone Health. During his five-year tenure, Dr. Weiss was responsible for the global launch of seven products in the contraception, urology, and infertility space, and designed, implemented and oversaw multiple late-stage clinical trials.  He also provided all medical due diligence for business development projects.

Prior to joining Teva in 2010, Dr. Weiss founded and was Chief Medical Officer of FibroControl, a medical device company developing a minimally invasive technique to treat uterine fibroids. He was concurrently a medical and biotech research advisor to a private equity firm.

Dr. Weiss' clinical experience has focused on obstetrics and gynecology.  He specialized in pelvic floor health and gynecological surgery and, while in private practice, started a Bladder Health Center focused on the diagnosis and treatment of lower urinary tract symptoms including female incontinence.

Dr. Weiss earned his M.D. at The Ohio State University College of Medicine and completed his residency in Obstetrics and Gynecology at the Albert Einstein College of Medicine Montefiore program. He received a MBA from George Washington University. He is extensively published, and holds multiple patents.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies.  Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected contributions of Dr. Weiss' employment at Juniper. Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  These risks and uncertainties include, but are not limited to: risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process; the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch, if such product candidates are approved; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Juniper Pharmaceuticals' ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from currently approved therapies and from other companies developing products for similar uses; risk associated with Juniper Pharmaceuticals' ability to manage operating expenses and/or obtain additional funding to support its business activities; and risks associated with Juniper Pharmaceuticals' dependence on third parties.  For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2015. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. 

Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 /

Amy Covino
Tell Med Strategies
(201) 774-3111 /

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Follow us on LinkedIn  

Logo -

To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.